Drug

CSPC Pharma Presents SYS6002 Phase I Data at IGCS 2026 – Nectin‑4 ADC Shows 35.9% ORR in Previously Treated Advanced Cervical Cancer; Phase III Underway
ADC / XDCCancer

CSPC Pharma Presents SYS6002 Phase I Data at IGCS 2026 – Nectin‑4 ADC Shows 35.9% ORR in Previously Treated Advanced Cervical Cancer; Phase III Underway

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that data from the Phase I clinical study of SYS6002, a next‑generation Nectin‑4‑targeting antibody‑drug conjugate (ADC), as monotherapy for the treatment of previously…

Tong Ren Tang's Dingzhi Wan Receives Hong Kong Proprietary Chinese Medicine Registration – HKCMP Certificate Expands Neurological Wellness Product Line

Tong Ren Tang’s Dingzhi Wan Receives Hong Kong Proprietary Chinese Medicine Registration – HKCMP Certificate Expands Neurological Wellness Product Line

Sino Biopharmaceutical Completes Phase III Enrollment for TQC3721 Inhaled PDE3/4 Inhibitor in COPD – Dual‑Target Therapy Eyes First‑in‑China Approval

Sino Biopharmaceutical Completes Phase III Enrollment for TQC3721 Inhaled PDE3/4 Inhibitor in COPD – Dual‑Target Therapy Eyes First‑in‑China Approval

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise
NovartisNYSE: NVS

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

BeBetter Medicine TechnologyClinical trial approval / initiation

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Clinical trial resultsHinova Pharmaceuticals

Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment – First THR-β Agonist Candidate in China

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU
NovartisNYSE: NVS

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Show More